Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose lanreotide treatment scheme in acromegalic patients poorly responsive to standard doses
2012-005313-39Phase 3Completed
- Sponsor
- ASST Spedali Civili di Brescia
- Start
- Mar 2013
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, single-arm trial of lanreotide in acromegaly, sponsored by ASST Spedali Civili di Brescia. Primary endpoint: Biochemical control of acromegaly. Started Mar 2013; status: completed.
02
Drugs
lanreotide
03
Conditions
acromegaly
Beyond the preview
Go deeper on 2012-005313-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005313-39.